Referenced in: none

Automatically associated channels: Kv1.5

Title: Selective Kv1.5 blockers: development of (R)-1-(methylsulfonylamino)-3-[2-(4-methoxyphenyl)ethyl]-4-(4-methoxyphenyl)-2-imidazolidinone (KVI-020/WYE-160020) as a potential treatment for atrial arrhythmia.

Authors: Benjamin E Blass, Andrew Fensome, Eugene Trybulski, Ronald Magolda, Stephen J Gardell, Kun Liu, Manoj Samuel, Irene Feingold, Christine Huselton, Chris M Jackson, Laurent Djandjighian, Douglas Ho, James Hennan, John M Janusz

Journal, date & volume: J. Med. Chem., 2009 Nov 12 , 52, 6531-4

PubMed link: http://www.ncbi.nlm.nih.gov/pubmed/19888755

Abstract
Atrial fibrillation is the most prevalent form of cardiac arrhythmia. Current treatments extend the atrial effective refractory period by nonselective blockade of cardiac ion channels. An alternative approach selectively targeting the Kv1.5 ion channel offers the opportunity for therapeutic benefit with decreased risk of adverse cardiovascular events. KVI-020 (4g) successfully demonstrated antiarrhythmic efficacy in a canine arrhythmia model, and these findings support its utility as an antiarrhythmic agent.